🔗 Share this article

While the United States undertakes unprecedented revisions to its vaccination recommendations, one figure appears in a surprising turn: Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by casting doubt on Covid vaccinations throughout the pandemic and has zeroed in on potential deaths after COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Schedule

Health officials had intended to announce radical changes to the childhood vaccine schedule recently, aligning the US with the Danish immunization schedule, sources say – a substantial departure that would put the US at odds with many the international standard with no evidence for public health gain. This reveal has been delayed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is set to speak at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to run the division this year.

Consolidating Power at the FDA

This interim role might represent a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing some childhood shot schedules in the US so as to align more similar to the Danish model, a society with universal health coverage and a population approximately the size of the state of Wisconsin.

So far statements, she has persisted in emphasizing on vaccines – typically the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Expertise

Høeg has no obvious track record in medication creation, oversight or leadership, which has been standard for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a scientific study. She is not versed in leading a major agency. She is not an expert in industry regulation.”

Past directors of CBER would “grasp legal statutes and the science of medication creation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that prior appointees who headed CBER have had.”

CDER has an vast range of responsibilities at the FDA, the former commissioner pointed out.

“The public just focuses on the innovative therapies, but the off-patent medication office approves a multitude of generic medications. There is also a biologic copycat branch, non-prescription drug unit and more, and all of those have to be managed,” she noted. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a significant management component to the job, which oversees in excess of 5,000 personnel. “It is a massive management job, if you execute it properly,” Woodcock said.

Agency Reaction and Contentious Policies

When asked about concerns about Høeg’s fitness for the role and whether this selection represents increased cooperation among regulatory chiefs on vaccines, a spokesperson said that the “inquiries are based on incorrect premises”.

“Her experience matches the responsibilities of her job,” the representative explained, citing the time Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg inherits the commissioner’s new fast-track approval initiative, a contentious rapid therapy clearance system that apparently troubled her former heads. “By what process are these therapies being picked for this fast-track system? Who is making the choices?” Dr. Howard asked. “There is a lot of lack of transparency occurring at the FDA right now.”

In general, he said, “the FDA seems to be moving towards laxer rules of most medications, with the exception of shots.”

Established History on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if concerning, history, Howard observe. She authored a analysis using non-validated volunteer-provided data to estimate the frequency of heart inflammation after Covid immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the current federal leadership encompassed altering regulations for recently developed shots and discontinuing “optional” vaccines, she said post-election on a podcast. At the FDA, Høeg has according to sources floated the idea of barring young men from getting Covid vaccinations.

“She’s an all-around ideologue who begins with her beliefs and tailors the evidence to retrofit the science in a extremely deceptive, untruthful way,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg became part of other skeptics, {like|